Scotiabank raised the firm’s price target on Teva (TEVA) to $40 from $35 and keeps an Outperform rating on the shares. The firm is positive on the stock following Q4 results and increased its price target on the stock due to the company’s execution continuing to exceed expectations, the analyst tells investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA: